Company intelligence / Profile preview

Coyote Bioscience

Beijing, Beijing, Chinaen.coyotebio.com ↗

Ownership: Private
Development stage: Other

Overview

Coyote Bioscience has developed multiple generations of rapid molecular diagnostic products for point-of-care testing. Their FlashDetect™ system enables fast PCR-based pathogen detection with international regulatory approvals. The company played a significant role during the COVID‑19 pandemic by providing rapid testing solutions globally. Their technologies have been validated in major outbreaks including Ebola and Zika.

Therapeutic areas: Women's HealthGastroenterologyOncologyInfectious Diseases
Modalities: DeviceMolecular diagnostic platform (for nucleic acid detection, qPCR, etc.)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Coyote Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coyote Bioscience.

Explore the full profile